Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) CEO Bruce C. Cozadd sold 6,500 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $144.25, for a total transaction of $937,625.00. Following the completion of the transaction, the chief executive officer now owns 464,058 shares of the company's stock, valued at $66,940,366.50. This trade represents a 1.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Jazz Pharmaceuticals Stock Up 1.7 %
Shares of Jazz Pharmaceuticals stock traded up $2.36 during midday trading on Friday, hitting $138.81. The company's stock had a trading volume of 1,226,548 shares, compared to its average volume of 763,953. The firm has a market capitalization of $8.43 billion, a P/E ratio of 19.55, a PEG ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a 50-day simple moving average of $127.85 and a 200-day simple moving average of $119.83.
Wall Street Analyst Weigh In
JAZZ has been the topic of a number of research reports. Robert W. Baird boosted their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a research note on Monday, November 18th. JPMorgan Chase & Co. boosted their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. TD Cowen reduced their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a research report on Thursday, November 7th. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and lifted their price objective for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Finally, Royal Bank of Canada cut their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Buy" and an average price target of $189.40.
Read Our Latest Research Report on JAZZ
Institutional Trading of Jazz Pharmaceuticals
A number of hedge funds have recently made changes to their positions in JAZZ. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at approximately $25,000. Quadrant Capital Group LLC grew its holdings in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after acquiring an additional 101 shares in the last quarter. Elequin Capital LP increased its stake in shares of Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares during the last quarter. CoreFirst Bank & Trust acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $28,000. Finally, Allianz SE purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth $29,000. 89.14% of the stock is owned by hedge funds and other institutional investors.
Jazz Pharmaceuticals Company Profile
(
Get Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
See Also
Before you consider Jazz Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.
While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
